<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006021</url>
  </required_header>
  <id_info>
    <org_study_id>20000156</org_study_id>
    <secondary_id>CDR0000068033</secondary_id>
    <secondary_id>SCCC-2000010</secondary_id>
    <nct_id>NCT00006021</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma</brief_title>
  <official_title>Phase I/II Trial of Arsenic Trioxide (As2O3) With Ascorbic Acid in the Treatment of Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Vitamin C may increase the effectiveness of arsenic trioxide by&#xD;
      making cancer cells more sensitive to the drug.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to determine the effectiveness of arsenic trioxide plus vitamin C&#xD;
      in treating patients who have recurrent or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of arsenic trioxide when administered with ascorbic&#xD;
           acid in patients with recurrent or refractory multiple myeloma.&#xD;
&#xD;
        -  Determine the therapeutic efficacy of this treatment combination in these patients.&#xD;
&#xD;
        -  Determine the expression of MDR and Bcl-xL genes and the intracellular levels of GSH in&#xD;
           these patients before and after this treatment regimen and assess whether these measures&#xD;
           have prognostic value.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of arsenic trioxide.&#xD;
&#xD;
        -  Phase I: Patients receive arsenic trioxide IV over 1-4 hours and ascorbic acid IV over&#xD;
           5-10 minutes on days 1-5 weekly for 5 weeks. Treatment continues every 7 weeks for up to&#xD;
           6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of arsenic trioxide until the maximum&#xD;
      tolerated dose (MTD) is reached. The MTD is defined as the dose preceding that at which 2 of&#xD;
      3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive the MTD of arsenic trioxide with ascorbic acid as outlined&#xD;
           above.&#xD;
&#xD;
      Patients are followed monthly for up to 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 31-43 patients (6-18 for phase I and 16-25 for phase II) will&#xD;
      be accrued for this study within 2.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease response as measured by M protein quantitation and the percentage of plasma cell infiltration in bone marrow biopsies after every course</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by CTCAE criteria</measure>
  </secondary_outcome>
  <enrollment type="Actual">22</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ascorbic acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed multiple myeloma&#xD;
&#xD;
               -  M-protein by serum protein electrophoresis or urine protein electrophoresis&#xD;
&#xD;
               -  Quantitative determination of immunoglobulin&#xD;
&#xD;
               -  Bone marrow biopsy and aspirate with a plasma cell count greater than 10%&#xD;
&#xD;
               -  Refractory or chemoresistant disease defined as failure to respond (less than 50%&#xD;
                  reduction in M protein level) or progression within 2 months after receiving at&#xD;
                  least 2 chemotherapy regimens including:&#xD;
&#xD;
                    -  Alkylating based regimen (melphalan) in combination with steroids&#xD;
                       (prednisone) or other chemotherapy regimens (e.g., vincristine, bleomycin,&#xD;
                       melphalan, cyclophosphamide, and prednisone or vincristine, carmustine,&#xD;
                       doxorubicin, and prednisone)&#xD;
&#xD;
                    -  Vincristine, doxorubicin, and dexamethasone (VAD) regimen&#xD;
&#xD;
                    -  Pulse therapy with high dose steroids alone&#xD;
&#xD;
                    -  High dose alkylating agent and autologous stem cell transplantation&#xD;
&#xD;
                    -  Allogeneic bone marrow transplantation&#xD;
&#xD;
               -  Plateau phase defined as M protein in the serum or urine for more than 6 weeks&#xD;
                  despite response to prior therapy&#xD;
&#xD;
                    -  Must have received at least 2 of the chemotherapy regimens listed above or&#xD;
                       equivalent regimens&#xD;
&#xD;
               -  Recurrent disease defined as progression more than 2 months after initial therapy&#xD;
                  and failure to respond (less than 50% reduction or progression in M protein&#xD;
                  levels) to 1 chemotherapy regimen listed above or other salvage regimens (e.g.,&#xD;
                  high-dose cyclophosphamide or topotecan)&#xD;
&#xD;
                    -  Must have received VAD or other equivalent chemotherapy regimen&#xD;
&#xD;
                    -  Should be considered for autologous or allogenic transplantation&#xD;
&#xD;
                    -  Prior local radiotherapy allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 2,000/mm^3*&#xD;
&#xD;
          -  Platelet count at least 50,000/mm^3* NOTE: *Unless attributable to bone marrow&#xD;
             infiltration by multiple myeloma&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 3 mg/dL&#xD;
&#xD;
          -  Transaminases less than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiac arrhythmias including recurrent supraventricular arrhythmia, any type of&#xD;
             sustained ventricular arrhythmia, or conduction block (atrioventricular block grade II&#xD;
             or III, left bundle branch block)&#xD;
&#xD;
          -  Ejection fraction at least 30%&#xD;
&#xD;
          -  No uncontrolled ischemic heart disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 4 months&#xD;
             after study&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No grade 3 or higher neurological disorder, including seizure disorders&#xD;
&#xD;
          -  No underlying medical condition that would preclude study&#xD;
&#xD;
          -  No other active malignancy except adequately treated basal or squamous cell carcinoma&#xD;
             of the skin or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent steroid treatment allowed except for primary treatment of myeloma&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent local radiotherapy for pain or symptom control allowed provided the pain or&#xD;
             symptom is not related to disease progression&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent ascorbic acid supplements&#xD;
&#xD;
          -  No other concurrent investigational drug or therapy&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelvin Lee, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami Sylvester Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist-South Miami Regional Cancer Program</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH, Lee KP. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res. 2002 Dec;8(12):3658-68.</citation>
    <PMID>12473574</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 14, 2016</last_update_submitted>
  <last_update_submitted_qc>December 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

